Predictive and prognostic value of CA 19-9 in resected pancreatic adenocarcinoma

Journal of Gastrointestinal Surgery

Volumn 13, Issue 11, 2009, Pages 2050-2058

  Barton, Joshua G ^a   Bois, John P ^a   Sarr, Michael G ^a   Wood, Christina M ^a   Qin, Rui ^a   Thomsen, Kristine M ^a   Kendrick, Michael L ^a   Farnell, Michael B ^a  

^a MAYO CLINIC   (United States)

Author keywords

CA 19 9 antigen; Pancreatic carcinoma; Pancreatic ductal carcinoma; Predictive value of tests; Survival analysis

Indexed keywords

BILIRUBIN; CA 19-9 ANTIGEN;

AGED; ARTICLE; BLOOD; FEMALE; HUMAN; LYMPH NODE; MALE; MIDDLE AGED; MORTALITY; PANCREAS CARCINOMA; PANCREAS TUMOR; PANCREATICODUODENECTOMY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

AGED; BILIRUBIN; CA-19-9 ANTIGEN; CARCINOMA, PANCREATIC DUCTAL; FEMALE; HUMANS; LYMPH NODES; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 77952973346     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-009-0849-z     Document Type: Review

References (18)

1. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 1979;5:957-971. doi:10.1007/BF01542654.
2. Tian F, Appert HE, Myles J, Howard JM. Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma. Ann Surg 1992;215:350-355. doi:10.1097/00000658-199204000-00008
3. Frebourg T, Bercoff E, Manchon N, et al. The evaluation of CA 19-9 antigen level in the early detection of pancreatic cancer. A prospective study of 866 patients. Cancer 1988;62:2287-2290. doi:10.1002/1097-0142(19881201)62:11<2287::AID-CNCR2820621103>3.0.CO;2-H
4. Nakao A, Oshima K, Nomoto S, et al. Clinical usefulness of CA-19-9 in pancreatic carcinoma. Semin Surg Oncol 1998;15:15-22. doi:10.1002/(SICI)1098-2388(199807/08)15:1<15::AID-SSU4>3.0. CO;2-Z
5. Montgomery RC, Hoffman JP, Riley LB, Rogatko A, Ridge JA, Eisenberg BL. Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas. Ann Surg Oncol 1997;4:551-556. doi:10.1007/BF02305535.
6. Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-delCastillo C, Warshaw AL. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 2006;24:2897-2902. doi:10.1200/JCO.2005.05.3934.
7. Yasue M, Sakamoto J, Teramukai S, et al. Prognostic values of preoperative and postoperative CEA and CA19.9 levels in pancreatic cancer. Pancreas 1994;9:735-740. doi:10.1097/ 00006676-199411000-00011.
8. Schlieman MG, Ho HS, Bold RJ. Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg 2003;138: 951-955, discussion 955-956. doi:10.1001/archsurg.138. 9.951.
9. Safi F, Schlosser W, Falkenreck S, Beger HG. Prognostic value of CA 19-9 serum course in pancreatic cancer. Hepatogastroenterol-ogy 1998;45:253-259.
10. Forsmark CE, Lambiase L, Vogel SB. Diagnosis of pancreatic cancer and prediction of unresectability using the tumor-associated antigen CA19-9. Pancreas 1994;9:731-734. doi:10. 1097/00006676-199411000-00010.
11. Mann DV, Edwards R, Ho S, Lau WY, Glazer G. Elevated tumour marker CA19-9: clinical interpretation and influence of obstruc-tive jaundice. Eur J Surg Oncol 2000;26: 474-479 doi:10.1053/ ejso.1999.0925.
12. Kang CM, Kim JY, Choi GH, et al. The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer. J Surg Res 2007;140: 31 35. doi:10.1016/j.jss. 2006.10.007.
13. ® commercial location and research online service. Philadelphia, PA: LexisNexis, 2008.
14. Contal C, O'Quigley J. An application of changepoint methods in studying the effect of age on survival in breast cancer. Comput Stat Data Anal 1999;30:253-270.
15. Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduo-denectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 2006;10:1199-1210, discussion 1210-1211. doi:10.1016/j.gassur.2006.08.018.
16. Pawlik TM, Gleisner AL, Cameron JL, et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 2007;141:610-618. doi:10.1016/j. surg.2006.12.013.
17. Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 2006;13:1035-1046. doi:10.1245/ASO.2006.08.011.
18. Temudom T, Sarr MG, Douglas MG, Farnell MB. An argument against routine percutaneous biopsy, ERCP, or biliary stent placement in patients with clinically resectable periampullary masses: a surgical perspective. Pancreas 1995;11:283-288. doi:10.1097/00006676-199510000-00011.